Literature DB >> 34625923

Hepatocellular Carcinoma Tumor Microenvironment and Its Implications in Terms of Anti-tumor Immunity: Future Perspectives for New Therapeutics.

Basri Satilmis1, Tevfik Tolga Sahin2, Egemen Cicek1, Sami Akbulut1, Sezai Yilmaz1.   

Abstract

PURPOSE: Hepatocellular cancer is an insidious tumor that is often diagnosed in a later stage of life. The tumor microenvironment is the key to tumorigenesis and progression. Many cellular and non-cellular components orchestrate the intricate process of hepatocarcinogenesis. The most important feature of hepatocellular cancer is the immune evasion process. The present review aims to summarize the key components of the tumor microenvironment in the immune evasion process.
METHODS: Google Scholar and PubMed databases have been searched for the mesh terms "Hepatocellular carcinoma" or "Liver Cancer" and "microenvironment." The articles were reviewed and the components of the tumor microenvironment were summarized.
RESULTS: The tumor microenvironment is composed of tumor cells and non-tumoral stromal and immune cells. HCC tumor microenvironment supports aggressive tumor behavior, provides immune evasion, and is an obstacle for current immunotherapeutic strategies. The components of the tumor microenvironment are intratumoral macrophages (tumor-associated macrophages (TAM)), bone marrow-derived suppressor cells, tumor-associated neutrophils (TAN), fibroblasts in the tumor microenvironment, and the activated hepatic stellate cells.
CONCLUSION: There are intricate mechanisms that drive hepatocarcinogenesis. The tumor microenvironment is at the center of all the complex and diverse mechanisms. Effective and multistep immunotherapies should be developed to target different components of the tumor microenvironment.
© 2021. Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Fibroblasts; Hepatocellular cancer; Regulatory T cells; Tumor microenvironment; Tumor-associated macrophages

Mesh:

Year:  2021        PMID: 34625923     DOI: 10.1007/s12029-021-00725-8

Source DB:  PubMed          Journal:  J Gastrointest Cancer


  52 in total

Review 1.  Mechanisms of hepatic fibrogenesis.

Authors:  Scott L Friedman
Journal:  Gastroenterology       Date:  2008-05       Impact factor: 22.682

Review 2.  Hepatitis B virus integration, fragile sites, and hepatocarcinogenesis.

Authors:  Mark A Feitelson; Jungmin Lee
Journal:  Cancer Lett       Date:  2006-12-22       Impact factor: 8.679

3.  Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using liver stiffness measurement (FibroScan).

Authors:  Kyu Sik Jung; Seung Up Kim; Sang Hoon Ahn; Young Nyun Park; Do Young Kim; Jun Yong Park; Chae Yoon Chon; Eun Hee Choi; Kwang-Hyub Han
Journal:  Hepatology       Date:  2011-02-11       Impact factor: 17.425

Review 4.  Epidemiology and surveillance of hepatocellular carcinoma.

Authors:  Do Young Kim; Kwang-Hyub Han
Journal:  Liver Cancer       Date:  2012-06       Impact factor: 11.740

Review 5.  Hepatitis B virus pre-S mutants, endoplasmic reticulum stress and hepatocarcinogenesis.

Authors:  Hui-Ching Wang; Wenya Huang; Ming-Der Lai; Ih-Jen Su
Journal:  Cancer Sci       Date:  2006-08       Impact factor: 6.716

Review 6.  Natural history and prognosis of hepatitis B.

Authors:  Giovanna Fattovich
Journal:  Semin Liver Dis       Date:  2003-02       Impact factor: 6.115

Review 7.  Hepatocellular carcinoma: epidemiology and molecular carcinogenesis.

Authors:  Hashem B El-Serag; K Lenhard Rudolph
Journal:  Gastroenterology       Date:  2007-06       Impact factor: 22.682

8.  Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease.

Authors:  Anna S Lok; Leonard B Seeff; Timothy R Morgan; Adrian M di Bisceglie; Richard K Sterling; Teresa M Curto; Gregory T Everson; Karen L Lindsay; William M Lee; Herbert L Bonkovsky; Jules L Dienstag; Marc G Ghany; Chihiro Morishima; Zachary D Goodman
Journal:  Gastroenterology       Date:  2008-09-18       Impact factor: 22.682

9.  Surgery for hepatocellular carcinoma: does it improve survival?

Authors:  Jerome H Liu; Pauline W Chen; Steven M Asch; Ronald W Busuttil; Clifford Y Ko
Journal:  Ann Surg Oncol       Date:  2004-03       Impact factor: 5.344

10.  Surveillance for hepatocellular carcinoma in patients with cirrhosis improves outcome.

Authors:  Richard Todd Stravitz; Douglas M Heuman; Nisha Chand; Richard K Sterling; Mitchell L Shiffman; Velimir A Luketic; Arun J Sanyal; Adil Habib; Anastasios A Mihas; Ho-Chong S Giles; Daniel G Maluf; Adrian H Cotterell; Marc P Posner; Robert A Fisher
Journal:  Am J Med       Date:  2008-02       Impact factor: 4.965

View more
  3 in total

1.  Astragalus polysaccharide (APS) attenuated PD-L1-mediated immunosuppression via the miR-133a-3p/MSN axis in HCC.

Authors:  Lihua He; Kecheng Xu; Lizhi Niu; Lizhu Lin
Journal:  Pharm Biol       Date:  2022-12       Impact factor: 3.889

2.  ELOVLs Predict Distinct Prognosis Value and Immunotherapy Efficacy In Patients With Hepatocellular Carcinoma.

Authors:  Yu Zhang; Shujie Pang; Bo Sun; Minbo Zhang; Xiaoxiao Jiao; Linying Lai; Yiting Qian; Ning Yang; Wenzhuo Yang
Journal:  Front Oncol       Date:  2022-07-15       Impact factor: 5.738

Review 3.  The tumor microenvironment of hepatocellular carcinoma and its targeting strategy by CAR-T cell immunotherapy.

Authors:  Zhang Guizhen; Ji Guanchang; Liu Liwen; Wang Huifen; Ren Zhigang; Sun Ranran; Yu Zujiang
Journal:  Front Endocrinol (Lausanne)       Date:  2022-08-25       Impact factor: 6.055

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.